Preclinical

Preclinical : Anti-obesity effect of Cirpusins^® in High-Fat Diet-Induced Obese Mice

The animals (C57/BL6 mice) were first fed with a high-fat diet (HFD) for 27 days to induce obesity before supplementation with Cirpusins® for another 27 days. At the end of 55 days, animals were sacrificed and analyzed.

Results

• Untreated mice gained 7.84 grams of weight, while Cirpusins^® treated  animals gained  5.14, 3.95 and 4.34 grams  at 50, 100, and 200 mg/kg, respectively, resulting in  30.1%, 46.3%, and 40.9% reduction in weight gain at 50, 100, and 200 mg/kg, respectively, (Figure 2A)

Figure 2A: Anti-obesity effect of Cirpusins^® on mean change in the body weight (g) in HFD-induced obesity in mice model.
Values are expressed as means ± SEM (n = 6)

• Cirpusins^® treatment showed a dose-dependent reduction in both leptin and corticosterone levels in the serum (Figure 2B & 2C)

Figure 2B & 2C: Effect of Cirpusins^® in leptin concentration (pg/mL) (B) and Corticosterone concentration (pg/mL) (C) in HFD-induced obesity in mice model.
Values are expressed as means ± SEM (n = 6)

• Cirpusins^® treatment showed a significant decrease in all lipid parameters such as triglycerides, total cholesterol, and VLDL levels
• Cirpusins^® supplementation was found to be safe with no reported adverse events